中文摘要：

基于益生菌的結(jié)直腸癌（CRC）生物療法因腫瘤靶向能力差和復(fù)雜腫瘤微環(huán)境中生物活性有限而面臨重大挑戰(zhàn)。本研究顯示，通過(guò)錳能夠增強(qiáng)乳酸乳球菌（Lactobacillus reuteri，L. reuteri）固有的生物活性，包括增殖、代謝和結(jié)腸定植，從而促成了錳工程菌株（MnLR）的構(gòu)建。口服給藥MnLR及其代謝底物甘油（MnLR/Gly）可促進(jìn)L. reuteri及其抗腫瘤代謝產(chǎn)物在結(jié)腸腫瘤中的富集。在多種前臨床結(jié)腸腫瘤模型中，單獨(dú)使用MnLR/Gly即可實(shí)現(xiàn)95.6%的原位腫瘤生長(zhǎng)抑制、肝轉(zhuǎn)移減少62.1%，并提供持久保護(hù)，75%的預(yù)防性處理小鼠長(zhǎng)期無(wú)腫瘤，62.5%對(duì)腫瘤再挑戰(zhàn)具有抵抗力。從機(jī)制上看，MnLR/Gly可誘導(dǎo)腫瘤內(nèi)及外周樹(shù)突狀細(xì)胞成熟、M1型巨噬細(xì)胞極化以及效應(yīng)T細(xì)胞反應(yīng)。在原位CRC兔模型中，GlyMnLR腸溶膠囊顯示出與標(biāo)準(zhǔn)化療相當(dāng)?shù)娘@著抗腫瘤效果，同時(shí)表現(xiàn)出良好的安全性。這些發(fā)現(xiàn)表明，MnLR是一種有效的單獨(dú)益生菌療法，用于CRC的預(yù)防和治療。

英文摘要：

Probiotic-based biotherapy for colorectal cancer (CRC) faces significant challenges due to poor tumor-targeting and limited bioactivities within the complex tumor microenvironment. This study shows that Lactobacillus reuteri (L. reuteri)’s inherent bioactivities, including proliferation, metabolism, and colorectal colonization, can be enhanced by manganese, prompting the fabrication of a manganese-engineered strain (MnLR). Oral administration of MnLR with its metabolic substrate-glycerol (MnLR/Gly) promotes the enrichment of L. reuteri and its antitumor metabolites within colon tumors. Across multiple preclinical colon tumor models, MnLR/Gly alone achieves a 95.6% inhibition of orthotopic tumor growth, liver metastases reduction by 62.1%, and confers durable protection, with 75% of prophylactically treated mice remaining long-term tumor-free and 62.5% resisting tumor rechallenge. Mechanistically, MnLR/Gly induces both intratumoral and peripheral dendritic cell maturation, M1 macrophage polarization, and effector T-cell responses. In orthotopic CRC rabbit models, GlyMnLR enteric capsules demonstrate significant antitumor efficacy comparable to standard chemotherapy while exhibiting favorable safety. These findings highlight MnLR as an effective standalone probiotic therapy for CRC prevention and treatment.

論文信息：

論文題目：Manganese-engineered Lactobacillus Reuteri with enhanced antitumor and immunomodulatory activities for colorectal cancer prevention and treatment

期刊名稱(chēng)：Nature Communications

時(shí)間期卷：17, Article number: 761(2026)

在線(xiàn)時(shí)間：2025年12月19日

DOI： doi.org/10.1038/s41467-025-67437-6

產(chǎn)品信息：

貨號(hào)：C-005

規(guī)格：5ml

品牌：Liposoma

產(chǎn)地：荷蘭

名稱(chēng)：Clodronate Liposomes氯膦酸鹽脂質(zhì)體

辦事處：靶點(diǎn)科技

Clodronate Liposomes氯膦酸鹽脂質(zhì)體在小鼠結(jié)腸癌模型清除巨噬細(xì)胞和外周單核巨噬細(xì)胞。荷蘭Liposoma巨噬細(xì)胞清除劑ClodronateLiposomes見(jiàn)刊于Nature Communications：錳工程乳桿菌增強(qiáng)抗腫瘤和免疫調(diào)節(jié)活性用于結(jié)直腸癌的預(yù)防和治療。

Liposoma巨噬細(xì)胞清除劑Clodronate Liposomes氯膦酸二鈉脂質(zhì)體清除肺泡巨噬細(xì)胞和單核巨噬細(xì)胞的材料和方法：

In vivo cell depletion

clodronate-encapsulated liposomes (200?μl per mouse; LIPOSOMA, Netherlands) on days 6, 2, and 1 before tumor inoculation, and on days 4, 8, and 12 following tumor inoculation.

材料和方法文獻(xiàn)截圖：